Tacrolimus: 8 agencies, 2007–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 19.2 years separate the first record, 9 May 2007 at HAS (France), from the most recent, 2026 at PBAC (Australia).
SMC (Scotland) changed its position: restricted on 5 Mar 2010, recommended by 13 Apr 2015.
No assessment is on file from CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for tacrolimus, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 3 of 34 records date from 2023 or later.
The programme is broad: 8 distinct indication wordings are recorded for tacrolimus by the agencies that label one in English (AWMSG, PBAC and SMC).
4 of these 34 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess tacrolimus, on 9 May 2007; AOTMIT (Poland) did not open a file until 15 Dec 2023 — an unusually long tail of 16.6 years between the earliest and latest system to look at it.
The record arrives in waves: 8 separate years each carry two or more decisions, spread across 17 years in total.
7 of the 8 agencies here assessed tacrolimus more than once, HAS (France) most often at 13 entries — repeat review is the norm for this molecule rather than the exception.
8 of the 18 agencies in this archive hold a record for tacrolimus.
The full ledger for tacrolimus reads 17 recommended, 8 other, 3 restricted and 2 not recommended, with 4 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2025 | Atopic dermatitis | Recommended | source |
| AOTMIT (Poland) | 15 Dec 2023 | Modigraf reimbursement recommendation | recommended | source |
| HAS (France) | 20 Jul 2022 | Re-assessment of SMR | SMR insufficient · ASMR V | source |
| PHARMAC (New Zealand) | 8 Feb 2018 | Atopic dermatitis in children and adults | PTAC advice: No Formal Recommendation · decision reached | source |
| CONITEC (Brazil) | 18 Jan 2016 | Imunossupressores para transplantes pulmonares | incorporated into SUS | source |
29 further decisions for tacrolimus, across 7 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 19 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 34 decisions for tacrolimus from 8 agencies, 2007 to 2026. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.